Clinical trials: Hand-foot Syndrome
Dermatologic Complications, Palmar-plantar Erythrodysesthesia
Pyridoxine in Preventing Hand-Foot Syndrome Caused by Capecitabine in Patients With Cancer
RATIONALE: Pyridoxine may help prevent hand-foot syndrome caused by capecitabine in patients with cancer. It is not yet known whether pyridoxine is more effective than a placebo in preventing hand-foot syndrome in patients with…
- Conditions
- Dermatologic Complications, Palmar-plantar Erythrodysesthesia, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00486213
- Testing
- pyridoxine hydrochloride
- Where
- Singapore
- Volunteers
- 210 people
- Sponsor
- National Cancer Centre, Singapore
Breast Cancer
Effectiveness of an N-acetylcysteine and Urea-based Cream in Prevention of Capecitabine-induced HAND-foot Syndrome in Breast Cancer Patients
Breast cancer (BC) is the most frequent tumour in women. To date, among the available treatments, the use of Capecitabine, an oral prodrug of fluorouracil, has been shown activity in different setting.
- Trial name
- HAND-TO-HAND (NCT06639178)
- Testing
- DECLARAN cream
- Where
- 2 sites in Italy
- Volunteers
- 25 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Breast Cancer, Colorectal Cancer
Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Conditions
- Breast Cancer, Colorectal Cancer, Pain
- Trial name
- NCT00305643
- Testing
- Capecitabine, Celecoxib, Radiation Therapy
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Hand-foot Syndrome
Hydration Based on Thoitaine, Aloe Vera and Calendula, in the Prevention of Hand-Foot Syndrome in Patients Using Capecitabine
Hand-foot syndrome (HFS) is a very common adverse event of many chemotherapeutic agents, especially capecitabine. The HFS can considerably interfere patient quality of life (QoL).
- Trial name
- TACX Care (NCT04833998)
- Testing
- Extremecare
- Where
- Brazil
- Volunteers
- 54 people
- Sponsor
- Instituto Brasileiro de Controle do Cancer
Thyroid Cancer, Hand-foot Syndrome
Oral Mecobalamin for TKI-Associated Hand-Foot Syndrome in Advanced Thyroid Cancer
This study evaluates the efficacy and safety of oral mecobalamin for the treatment of tyrosine kinase inhibitor (TKI)-associated hand-foot syndrome (HFS) in patients with advanced thyroid cancer.
- Trial name
- Mec-HFS-TC (NCT07911891)
- Testing
- Mecobalamin, Urea Ointment
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Li Zhihui
Hand Foot Skin Syndrome
Topical Henna Preparation for the Treatment of Hand Foot Skin Syndrome
The purpose of this study is to determine whether henna paste is effective in the treatment of hand-foot skin syndrome, induced by the drugs Capecitabine and pegylated liposomal doxorubicin.
- Trial name
- NCT01097850
- Testing
- henna paste
- Sponsor
- Northwestern University
Type 2 Inflammatory Disorders
Compassionate Use or Expanded Access of Dupilumab
Provide Compassionate Use or Expanded Access of Dupilumab
- Trial name
- NCT04776694
- Testing
- Dupilumab
- Sponsor
- Regeneron Pharmaceuticals
Patients With Solid Tumors
Traditional Chinese Medicine Hand-Foot Soak for Chemotherapy-Induced Peripheral Neuropathy and Hand-Foot Syndrome
Systemic therapies, including chemotherapy, targeted therapy, and immunotherapy, are cornerstones of modern oncology and have significantly extended patient survival.
- Trial name
- NCT07375446
- Testing
- Traditional Chinese Medicine
- Volunteers
- 300 people
- Sponsor
- Peking University Third Hospital
Microbiota
Study on Skin Microbiome of HFS
To skin microecology and breast cancer chemotherapy drug therapy as the breakthrough point, disease prevention and treatment of breast cancer in China, the important scientific problems in basic research, through in-depth study…
- Trial name
- NCT04132713
- Testing
- Capecitabine 150Mg Oral Tablet
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Henna, Hand-Foot Syndrome
Effectiveness of the Henna Application in Patients With Hand-Foot Syndrome: Nested Case-Control Study
Introduction: There is an explanation that there is a connection between the application of henna and the occurrence of hand-foot syndrome, and the purpose and progression of this interaction.
- Conditions
- Henna, Hand-Foot Syndrome, Case-Control Study
- Trial name
- [Henna] (NCT06832501)
- Testing
- Henna
- Where
- Turkey (Türkiye)
- Volunteers
- 84 people
- Sponsor
- Hacettepe University
Breast Cancer
A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
This 3 arm study will compare the prophylactic effect of topical corticosteroids, Bepantol or placebo on hand-foot syndrome in patients receiving Xeloda for treatment of metastatic breast cancer, metastatic colorectal cancer or…
- Trial name
- NCT00661102
- Testing
- Corticosteroids, capecitabine [Xeloda], dexpantenol [Bepantol]
- Where
- 35 sites in Brazil
- Volunteers
- 598 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Chemotherapeutic Agent Toxicity
Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer
RATIONALE: Nicotine patches may reduce hand-foot syndrome in patients receiving capecitabine for metastatic breast cancer. It is not yet known which nicotine patch regimen may be more effective in reducing hand-foot syndrome.
- Conditions
- Breast Cancer, Chemotherapeutic Agent Toxicity, Palmar-plantar Erythrodysesthesia
- Trial name
- NCT00751101
- Testing
- Nicotine patch
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of California, San Francisco
Hand-Foot Syndrome, Breast Cancer
Ice Plant Intensive Cream for the Prevention of Hand-Foot Syndrome in Breast Cancer: Pilot Randomized Controlled Trial
The present pilot study investigates the feasibility of a prospective larger confirmatory study on the efficacy of Dr. Hauschka Med Ice Plant Intensive Cream for the prevention of hand-foot syndrome in patients with breast…
- Trial name
- WIn-HFS (NCT05755646)
- Testing
- Ice Plant Intensive Cream plus Standard Care, Standard Care
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- University Hospital Tuebingen
Erythrodysesthesia Syndrome
Photobiomodulation in the Treatment of Hand-foot Syndrome
A cytotoxic complication caused by chemotherapy is hand-foot syndrome, also known as palmar-plantar erythrodysesthesia (PPE). The mechanism is not yet clear, but it is thought that the chemotherapeutic agent generates…
- Trial name
- NCT05337423
- Testing
- Photobiomodulation, Moisturizer
- Where
- 2 sites in Uruguay
- Volunteers
- 8 people
- Sponsor
- University of Nove de Julho
Palmar-Plantar Erythrodysesthesia
The Topical Application of Vitamin B6 in Palmar-Plantar Erythrodysesthesia
The study is designed to test the effectiveness of topical B6 cream in patients that developed Palmar-Plantar Erythrodysesthesia (Hand foot syndrome).
- Trial name
- HFSB6 (NCT02625415)
- Testing
- Vitamin B6 cream
- Where
- 2 sites in Cyprus
- Volunteers
- 54 people
- Sponsor
- Cyprus University of Technology
Palmar-Plantar Erythrodysesthesia, Breast Cancer
Study of 0.1% Uracil Topical Cream (UTC) for the Prevention of Hand-Foot Syndrome
The purpose of this research study is to see if combining uracil cream (UTC) with capecitabine (Xeloda) can prevent Hand-Foot Syndrome.
- Trial name
- NCT01100463
- Testing
- Cream, 0.1% Uracil Cream
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Nanometics (d.b.a. PHD Biosciences)
Hand-foot Syndrome
Study of Pyridoxine for Hand-Foot Syndrome
Although pyridoxine has been used empirically for the prevention of capecitabine associated hand-foot syndrome (HFS), its efficacy needs to be demonstrated in prospective controlled trials.
- Trial name
- NCT00446147
- Testing
- Pyridoxine
- Volunteers
- 389 people, healthy volunteers welcome
- Sponsor
- Asan Medical Center
Hepato Cellular Carcinoma (HCC), Hand Foot Skin Syndrome
SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin
SHIELD is a single-center, open-label, single-arm prospective study designed to evaluate whether pre-emptive topical indomethacin can reduce sorafenib-associated hand-foot syndrome (HFS) in patients with advanced hepatocellular…
- Trial name
- NCT07560566
- Testing
- Topical Indomethacin
- Where
- Taiwan
- Volunteers
- 39 people
- Sponsor
- National Taiwan University Hospital